

BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019

March 4, 2019

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 4, 2019-- [BioTime, Inc.](#) (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc., will present the [14th Annual Scientific Meeting of the Association For Ocular Pharmacology and Therapeutics](#) (AOPT 2019) on March 10, 2019 at 1pm EDT, as part of Session 12: "Disruptive Technologies: Ophthalmic Tools and Methods That Have Changed The Ways We See The Eye". AOPT 2019 will be held March 7-10, 2019 at the Hotel Monteleone in New Orleans, LA. Dr. Binette's presentation is entitled: "A Platform to Take on the Entire Progressive Retinal Degeneration Disease Continuum," and will describe the wide range of potential ophthalmic indications BioTime's proprietary pluripotent stem cell technology could address.

The Association for Ocular Pharmacology and Therapeutics (AOPT)

The Association for Ocular Pharmacology and Therapeutics is a global not-for-profit organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic applications. AOPT has a diverse, multi-national membership composed of preclinical and clinical scientists, students, and healthcare professionals. Members are from academic institutions, pharma and biotech industries, device companies, clinics and private practice. To achieve its mission the society organizes biennial conferences and provides editorial leadership for the peer-reviewed [Journal of Ocular Pharmacology and Therapeutics](#). For more information, please visit www.aopt.org or connect with the association on [Facebook](#) or [LinkedIn](#).

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime's pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime's lead cell replacement product candidate is OpRegen[®], a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime's lead cell delivery clinical program is Renevia[®], an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [YouTube](#). To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: <http://news.biotime.com>.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190304005290/en/>

Source: BioTime, Inc.

BioTime Inc. IR

Ioana C. Hone
ir@biotimeinc.com
(510) 871-4188

Solebury Trout IR

Gitanjali Jain Ogawa
Gogawa@troutgroup.com
(646) 378-2949